Orphan drugs for rare diseases: grounds for special status
Drug Development Research, 05/03/2012Picavet E et al.
Authors provide an overview of how the special status of orphan drugs can be put into practice with respect to registration, pricing and reimbursement. Adopting this special status in practice is possible, but not straightforward. Hence authors propose a number of policy recommendations, such as risk sharing arrangements, to take account of the special status of orphan drugs.
MDLinx connects healthcare professionals and patients to tomorrow's important medical news, while providing the pharmaceutical and healthcare industries with highly targeted interactive marketing, education, content, and medical research solutions.